MRD Business Highlights - Adaptive Biotechnologies achieved approximately $212 million in MRD revenue for the full year 2025[20] - The company experienced a 53% Compound Annual Growth Rate (CAGR) in pharma revenue[20] - Sequencing gross margins are approximately 65% in 2025[21] - Clinical volume growth shows a 44% CAGR from 2021 to 2025[22] - Over 50% of US heme-oncologists ordered clonoSEQ in 2025[22] - The company anticipates an average selling price (ASP) of approximately $1,400 per US clinical test in FY 2026[47] Immune Medicine (IM) Highlights - Adaptive Biotechnologies has generated over 5 million paired TCRs to antigen, significantly exceeding the 40,000 publicly available[52] - The company's Immune Medicine division had an annual cash burn of approximately $30 million in FY 2025, with a target to reduce it to $15 million to $20 million[60] Overall Company Goals - Adaptive Biotechnologies aims to achieve positive adjusted EBITDA and positive Free Cash Flow (FCF) for the whole company by the end of 2026[61]